Zusammenfassung
Die multiple Sklerose (MS) ist eine der häufigsten neurologischen Erkrankungen, für deren Ursache es bislang keine einheitliche Erklärung gibt. Grundpfeiler der Diagnostik ist die Klinik, ergänzt durch die Magnetresonanztomographie (MRT). Eine Liquoruntersuchung zum Nachweis der entzündlichen Genese nachgewiesener multifokaler Störungen ist bei allen unklaren Fällen und bei älteren Patienten erforderlich. Zur Bestätigung und Verlaufskontrolle sind elektrophysiologische Verfahren hilfreich.
Chapter PDF
Similar content being viewed by others
Literatur
Zitierte Literatur
Achiron A, Barak Y (2003) Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 74: 443–446
Arnett PA, Rao SM, Bernardin L et al. (1994) Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology 44: 420–425
Barkhof F, Filippi M, Miller D et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059–2069
Bartt RE (2006) Multiple sclerosis, Natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 19: 341–349
Bates D (1994) The diagnosis of multiple sclerosis. Proceedings of the MS forum modern management workshop. Professional Postgraduate Services Europe, Worthing, U. K.
Beck RW, Cleary PA, Anderson MM et al. (1992) A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326: 581–588
Bielekova B, Howard T, Packer AN et al. (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66: 483–489
Brønnum-Hansen H, Koch-Hendriksen N, Hyllested K (1994) Survival of patients with multiple sclerosis in Denmark: A nation-wide, longterm epidemiologic survey. Neurology 44: 1901–1907
Brück W, Stadelmann C (2005) The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 18(3): 221–224
Burt RK, Loh Y, Cohen B et al. (2009) Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: phase I/II study. Lancet Neurol 8: 244–253
Calabrese M, Filippi M, Rovaris M et al. (2008) Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuro Image 42: 1324–1328
Calabresi PA, Giovannoni G, Confavreux C et al. (2007) The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 69: 1391–1403
Chang A, Smith MC, Yin X et al. (2008) Neurogenesis in the chronic lesion of multiple sclerosis. Brain 131: 2366–2375
Chen JT, Collins DL, Atkins HL et al. (2008) Magnetisation transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63: 254–262
Coles AJ, Compston DA, Selmaj KW et al. (2008) Alemtuzumab vs interfernon-β-1 a in early multiple sclerosis. N Engl J Med 359: 1786–1801
Comi G, Pulizzi A, Rovaris M et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085–2092
Comi G, Martinelli V, Rodegher M et al. (2009) Effect of Glatirameracetat on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial. Lancet 374: 1503–1511
De Seze J, Arndt C, Jeanjean L (2008) Relapsing inflammatory optic neuritis: Is it neuromyelitis optica. Neurology 70: 2075–2076
De Stefano N, Matthews PM, Filippi M et al. (2003) Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 60: 1157–1162
Ebers GC (2008) Environmental factors and multiple sclerosis. Lancet Neurol 7: 268–277
Faiss JH (2006) MS – Nursing. In: Schmidt RM, Hoffmann F (Hrsg) Multiple Sklerose 4. Aufl. Urban & Fischer, München, S 389–394
Fazekas F, Offenbacher H, Fuchs S et al. (1988) Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38: 1822–1825
Fernando KTM, Tozer DJ, Miszkiel KA et al. (2005) Magnitization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 128: 2911–2925
Frohman EM, Racke MK, Raine CS (2006) Multiple Sclerosis – the plaque and its pathogenesis. N Engl J Med 354: 942–955
Frischer JM, Bramow S, Dal-Bianco A et al. (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132: 1175–1189
Gauthier SA, Berger AM, Liptak Z et al. (2009) Rate of brain atrophy in benign versus early multiple sclerosis. Arch Neurol 66: 234–237
Gladstone DE, Kenneth W, Zamkoff W et al. (2006) High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 63: 1388–1393
Goodin DS (2008) Disease-modifying therapy in multiple sclerosis. Update and clinical implications. Neurology (Suppl) 71: S8–S13
Hardt C (2006) Genetik und Umweltfaktoren. In: Schmidt RM, Hoffmann F (Hrsg) Multiple Sklerose. Urban & Fischer, München, S 19–31
Hartung HP, Gonsette R, König N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, mulitcentre trial. Lancet 360: 2018–2025
Hartung HP, Warnke C, Hohlfeld R, Kieseier BC (2009) Progressive multifokale Leukencepahlopathie. Nervenarzt 80: 1143–1153
Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: Genes, inflammation, and neurogeneration. Neuron 52: 61–76
Hauser SL, Weiner HL (2006) Natalizumab: immune effects and implications for therapy. Ann Neurol 59: 731–732
Hauser SL, Waubant E, Arnold DL et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676–688
Hawker K, O’Connor P, Freedman MS et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471
Heckl RW (1994) Multiple Sklerose: Klinik, Differenzialdiagnose, Behandlung. Thieme, Stuttgart
Henderson APD, Trip SA, Schlottmann PG et al. (2008) An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain 131: 277–287
Henze T (2005) Mitoxantron und Immunglobuline. Nervenheilkunde 24: 287–293
Hohlfeld R (1995) Multiple Sklerose. Akt Neurol 22: 125–130
Jilek S, Schluep M, Meylan P et al. (2008) Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131: 1712–1721
Kappos L, Bates D, Hartung HP et al. (2007) Natalizumab treatment for multiple sclerosis: Recommendations for patient selection and monitoring. Lancet Neurol 6: 431–441
Kesselring J (1997) Multiple Sklerose, 3. Aufl. Kohlhammer, Stuttgart (2. Aufl. 1993)
Krupp LB, Alvarez LA, LaRocca NG et al. (1988) Fatigue in multiple sclerosis. Arch Neurol 45: 435–437
Kuhlmann T, Miron V, Cuo Q et al. (2008) Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131: 1749–1758
Kumar R (2008) Approved and investigational uses of Modafinil: an evidencebased review. Drugs 68: 1803–1839
Kunkel A, Deppe R, Faiss J et al. (2009) Psychoedukatives Training für Patienten mit Multipler Sklerose: Inhalte und Evaluation. Poster 669; 82. Kongress der DGN. Aktuelle Neurologie 36 (Suppl 2): S 172
Kurtzke JF (1983) Epidemiology of multiple sclerosis. In: Hallpike JF, Adams CWM, Tourtellotte WW (eds) Multiple sclerosis. Chapman & Hall, London, pp 47–95
Littleton ET, Hbart JC, Palace J (2010) Modafinil for multiple sclerosis fatigue: Does it work? Clin Neurol Neurosurg 112 (1): 29–31
McDonald W, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121–127
Mikol DD, Barkhof F, Chang P et al. (2008) Comparison of subcutaneous interferon-β-1a with glatirameracetate in patients with relapsing remitting multiple sclerosis (The Rebif vs GlatiramerAcetate in Relapsing MS Disease [REGARD] study) a multicenter, randomized, parallel, open-label trial. Lancet Neurol 7: 903–914
Miller DH, Leary SM (2007) Primary progressive multiple sclerosis. Lancet Neurol 6: 903–912
Miller DH, Soon D, Fernando KT et al. (2007) MRI outcomes in a placebocontrolled trial of natalizumab in relapsing MS. Neurology 68: 1390–1401
Mills RJ, Yap L, Young CA (2007) Treatment for ataxia in multiple sclerosis. Cochrane Database of Systematic Reviews, Issue 1 Art No: CD005029
MSTKG (2006) Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 77: 1506–1518
Multiple Sklerose Konsensus Gruppe (MSTKG) (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75(Suppl 1): S2–S39
Mumford CJ, Wood NW, Kellar-Wood H (1994) The British isles survey of multiple sclerosis in twins. Neurology 44: 11–15
Neuhaus O, Kieseier BC, Hartung HP (2006) Therapeutic role of mitoxanrone in multiple sclerosis. Pharmacology & Therapeutics 109: 198–209
O’Connor P, Comi G, Montalban X et al. (2009a) Oral fingolimod (FTY 720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology 72: 73–79
O’Connor P, Filippi M, Arnason B et al. (2009b) 250 µg or 500 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre study. Lancet Neurol 8: 889–897
Paty DW, Li DK, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667
Pittock SJ, Weinshenker BG, Noseworthy JH et al. (2006) Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 63: 611–614
Polman CH, Reingold SC, Edan G et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions of the »McDonald criteria«. Ann Neurol 58(6): 840–846
Polman CH, O’Connor PW, Havrdova E et al. (2006) A randomized, placebocontrolled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910
Poser S, Wikström J, Bauer HJ et al. (1979) Clinical data and identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 40: 159–168
Poser CM, Paty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13: 227–231
Preiningerova J (2009) Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 18(7): 985–989
Pueyo V, Martin J, Fernandez J et al. (2008) Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Multiple Sclerosis 14: 609–614
Pulicken M, Gordon-Lipkin E, Balcer LJ et al. (2007) Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69: 2085–2092
Ramsaransing GSM, De Keyser J (2007) Predictive value of clinical characteristics for »benign« multiple sclerosis. Europ J Neurol 14: 885–889
Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622–2629
Rieckmann P (2006) Immunmodulatorische Stufentherapie der Multiplen Sklerose (MSTKG). Nervenarzt 77: 1506–1518
Rieckmann P, Kallmann B (2005) Neue Therapieansätze bei Multipler Sklerose. Nervenheilkunde 24: 294–300
Robinson I (1991) The context and consequences of communicating the diagnosis of multiple sclerosis. In: Wiethölter H, Dichgans J, Mertin J (eds) Current concepts in multiple sclerosis. Elsevier, Amsterdam, pp 17–22
Rocca MA, Colombo B, Falini A et al. (2005) Cortical adaption in patients with MS: A cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 4: 618–626
Ropper AH (2006) Selective treatment of multiple sclerosis. N Engl J Med 354: 965–967
Rudick RA, Stuart WH, Calabresi PA et al. (2006) Natalizumab plus Interferon beta – 1 a for relapsing multiple sclerosis. N Engl J Med 354: 911–923
Sailer M, Fazekas F, Gass A et al. (2008) Zerebrale und spinale MRT-Untersuchung bei Patienten mit klinisch isoliertem Syndrom oder gesicherter Multipler Sklerose. Fortschr Röntgenstr 180: 994–1001
Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of »benign« multiple sclerosis at 20 years. Neurology 68: 496–500
Scheglmann K (1995) Multiple Sklerose: Multimodal evozierte Potenziale in der Diagnose. TW Neurol Psychiatr 9 : 562–573
Schulz D, Kopp B, Kunkel A, Faiss JH (2006) Cognition in the early stage of multiple sclerosis. J Neurol 253: 1002–1010
Seidel D (1995) MS – Symptomatische Therapie und Rehabilitation. TW Neurol Psychiatr 9: 578–582
Simon JH, Jacobs LD, Campion MK et al. (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology 53: 139–148
Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Multiple Sclerosis 11: 425–432
Steinbrecher A, Dichgans J, Martin R (1995) Diagnostik und Therapie der multiplen Sklerose. Nervenheilkunde 14: 180–188
Stüve O, Marra CM, Jerome KR et al. (2006) Immune surveillance in multiple sclerosis patients treated with Natalizumab. Ann Neurol 59: 743–747
Stüve O, Marra CM, Cravens PD et al. (2007) Potential risk of progressive multifocal leukoencephalopathy with Natalizumab therapy: Possible interventions. Arch Neurol 64: 169–176
Thompson A (2004) Overview of primary progressive multiple sclerosis (PPMS): Similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult Scler 10: S2–S7
Tintoré M, Rovira A, Rio J et al. (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 70: 1079–1083
Trapp BD, Peterson J, Ransohoff RM et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5): 323–325
Vetrugno R, Stecchi S, Scandellari C et al. (2007) Sleep-wake and body core temperature rhythms in multiple sclerosis with fatigue. Clinical Neurophys 118: 228–234
Villar LM, Garcia-Barragán N, Sádaba MC et al. (2008) Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sciences 266: 34–37
Walderveen MAA van, Barkhof F, Pouwels PJW et al. (1999) Neuronal damage in T1-hypointensive multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46: 79–87
Weiner HL (2009) The challenge of multiple sclerosis: How do we cure an chronic heterogenous disease? Ann Neurol 65: 239–248
Weinshenker BC, Bass R, Rice GPA et al. (1989) The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 112: 133–146
Wingerchuk DM, Lennon VA, Pittok SJ et al. (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485–1489
Wolinsky JS, Narayana PA, O’Connor P et al. (2007) Glatiramer Acetat in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61: 14–24
Wood DD, Bilbao JM, O’Connors P, Moscarello MA (1996) Acute multiple sclerosis (Marburg type) is associated with developementally immature myelin basic protein. Ann Neurol 40: 18–24
Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N (2008) Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 131: 288–303
Zivadinov R (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 68 (Suppl): S72–S82
Weiterführende Literatur
Betts CD, Jones SJ, Fowler CG, Fowler CJ (1994) Erectile dysfunction in multiple sclerosis; associated neurological and neurophysiological deficits, and treatment of the condition. Brain 117: 1303–1310
Compston A (2006) McAlpine’s multiple sclerosis. 4th edn. Churchill Livingstone, London
Giovannoni G, Hartung H-P (1996) The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Op Neurol 9: 165–177
Kesselring J (1997) Multiple Sklerose. Kohlhammer, Stuttgart
Leary SM, Thompson AJ (2005) Primary progressive multiple sclerosis: Current and future treatment options. CNS Drugs 19(5): 369–376
McFarland HF, Frand JA, Albert PS et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758–766
Moulin DE (1989) Pain in multiple sclerosis. Neurol Clin 7: 321–331
Poser S (1996) Diagnose. In: Poser S (Hrsg) Taschenbuch Multiple Sklerose. Blackwell, Berlin, S 53–87
Seidel D (1995) Multiple Sklerose – Symptomatische Therapie und Rehabilitation. TW Neurol Psychiatr 9: 574–582
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661
Wiethölter H (2005) Schubprophylaxe mi Interferonen und Glatiramerazetat. Nervenheilkunde 24: 279–286
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Faiss, J., Wiethölter, H. (2011). Multiple Sklerose. In: Berlit, P. (eds) Klinische Neurologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16920-5_45
Download citation
DOI: https://doi.org/10.1007/978-3-642-16920-5_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-16919-9
Online ISBN: 978-3-642-16920-5
eBook Packages: Medicine (German Language)